

DAFTAR PUSTAKA

1. Global initiative for chronic obstructive lung disease pocket guide to COPD diagnosis, management, and prevention. A Guide for Health Care Professional. 2017.
2. Antariksa B, Djajalaksana S, Pradjanaparamita, Riyadi J, Yunus F, dkk. Penyakit Paru Obstruksi Kronik (PPOK) diagnosis dan penatalaksanaan. Perhimpunan Dokter Paru Indonesia.. Jakarta. 2011. Hal. 2-4
3. Indonesia KKR. Riset Kesehatan Dasar 2013. 2013.
4. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS *et al.* Chronic obstructive pulmonary disease: current burden and future projections. *European Respiratory Journal*. 2006;27(2):397-412.
5. Argiles JM, Alvarez B, Carbo N, Busquets S, Van Royen M, Lopez-Soriano F *et al.* The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. *Eur Cytokine Netw*. 2011;11: 552-9.
6. Langen RC, Schols AM, Kelders MC. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. *Am J Respir Cell Mol Biol*. 2006; 35:689-96.
7. Carbo N, Busquets S, van RM. TNF-alpha is involved in activating DNA fragmentation in skeletal muscle. *Br J Cancer*. 2008; 86:1012-6.
8. Agusti AG, Sauleda J, Miralles C. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010; 166:485-9.
9. Agusti A, Morla M, Sauleda J. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. *Thorax*. 2010; 59:483-7.
10. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofibrils. *Am J Respir Crit Care Med*. 2009; 166:479-84.
11. Narici M, Mafulli N. Sarcopenia: characteristics, mechanism, and functional significance. *British Med Bulletin*. 2010;95:139-59.

12. Kudo S, Ariga M, Kato J, Ohta K, Ohnishi M. Study of sarcopenia in patients with chronic obstructive pulmonary disease. Department of Internal Medicine. *Japan Respiratory* (2017) 22(Suppl.3), 4–87
13. Cruz-Jentoft AJ, Baeyens JP, Bauer JM. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. 2010; 39: 412–23.
14. Munhoz T, Marcelo F, Moreira CA, Rabelo LM, Boguszewski CL. Sarcopenia in COPD : relationship with COPD severity and prognosis. *J Bras Pneumol*. 2015; 41(5): 415–421.
15. PDGKI (Perhimpunan Dokter Spesialis Gizi Klinik Indonesia), Penyakit Paru Obstruksi Kronik (PPOK), dalam: Pedoman Tata Laksana Gizi Klinik, PDGKI, Jakarta, 2008: 89–91.
16. Galli C, Calder PC. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. *Ann Nutr Metab* 2009; 55: 123–39.
17. Smith GI, Atherton P, Reeds DN. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. *Am J Clin Nutr* 2011; 93: 402–412.
18. Keller H, Dreyer C, Medin J. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor– retinoid X receptor heterodimers. *Proc Natl Acad Sci U S A*. 2010; 90: 2160–2164.
19. Broekhuizen R, Wouters E, Creutzberg E. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. *Thorax* 2005; 60: 376–382.
20. Sugawara K, Takahashi H, Kasai C. Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. *Respir Med* 2010; 104: 1883–1889.
21. Fishman AP, Ellas JA, Fishman JA, Gripp MA, Senior RM, Pack AI. Chronic obstructive pulmonary disease. *Fishman's Pulmonary Diseases and Disorders*. McGraw Hill. 2008. 695–746

22. Loscalzo J. Chronic obstructive pulmonary disease. Harrison's Pulmonary and Critical care Medicine. Mcgrawi Hill Medical. 2010. 178–89
23. Vijayan VK. Chronic obstructive pulmonary disease. Indian Journal Medicine Respiratory. 2012;251–269
24. Morgan MJ , Liu Z. Crosstalk of reactive oxygen species and NF- κ B signaling. Cell Research. 2011; 21:103–115.
25. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22: 672 –688.
26. Stephens, Mark B, Yew, Kenneth S. Diagnosis of chronic obstructive pulmonary disease. American Family Physician. Vol. 78 Issue 1. 2008; 87 –92
27. Dahesia M. Pathogenesis of COPD. Clin Applied Immunol Rev. 2009; 339 –51
28. Pauwels RA. Chronic obstructive pulmonary disease. Eur Respir J. 2005; 20: 572–601.
29. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. The Lancet. 2011;378
30. Chung, K.F., Adcock, I.M. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008; 31(6): 1334 –56
31. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators of inflammation. 2013.
32. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R. Standardisation of spirometry. Eur Respir J. 2005. 319–338
33. Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effect of chronic obstructive pulmonary disease. Eur Respir J 2003;21: 347 – 60.
34. Donalson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004.

35. Lee B, Ahmed F, Hamm L, Teran F, Liu Y, Shah K *et al.* Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. 2014; 6(1): 130–136.
36. Liu M, Chen J, Huang D, Ke J, Wu W. A meta-analysis of proinflammatory cytokines in chronic heart disease. 2013; 6(1): 45–53.
37. Kim S, Kim H, Lee Y. Production of tumor necrosis factor-alpha by alveolar macrophages from patients with pulmonary tuberculosis. 2013; 3(1): 45–53.
38. Balkwill F. Tumor necrosis factor and cancer. *Nature Reviews Cancer* volume 9. 2009: 361–371.
39. Rennard SI, Hepp LM. Cigarette smoking and disease. In: Stockley RA, Rennard SI, Rabe K, Celli B, editors. *Chronic Obstructive Lung Disease (COPD)*. 1st ed. Massachusetts: Blackwell Publishing.
40. Wouters EFM. Local and systemic inflammation in COPD. *Proc Am Thorac Soc*. 2005;2:26–33.
41. Oca MM, Torres SH, Sanctis D, Mata A, Hernandez N, Talamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. *Eur Respir J*. 2005;26:390–7.
42. Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2008;157:1791–7.
43. Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010;164:1712–17.
44. Oudijk EJD, Nijhuis EHJ, Zwank MD, Graaf EA, Mager HJ, Coffey P *et al.* Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. *Thorax*. 2005;60:538–44.
45. Vilaró J, Ramirez-Sarmiento A, Martínez-Llorens JM, Mendoza T, Alvarez M, Sánchez-Cayado *Net al.* Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. *Respir Med*. 2010;104(12):1896–902.

46. Cesari M, Pedone C, Chiurco D, Cortese L, Conte ME, Scarlata S *et al.* Physical performance, sarcopenia and respiratory function in older patients with chronic obstructive pulmonary disease. *Age Ageing.* 2012;41(2): 237–41.
47. Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. *Clin Cases Miner Bone Metab.* 2014;11(3):177–80.
48. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F *et al.* Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* 2010;39(4):412–23.
49. Buchholz AC, Bartok C, Schoeller DA. "The validity of bioelectrical impedance models in clinical populations". *Nutr Clin Pract.* 2004; 19 (5): 433–46.
50. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddal H. A review of the measurement of grip strength in clinical and epidemiological studies : towards a standardised approach. *Age and aging.* 2011;40:423–9.
51. Norman K, Strobaus N, Smoliner C, Zochier D, Scheufele R. Determinants of hand grip strength, knee extension strength and functional status in cancer patient. *Clinical Nutrition.* 2010;29:586–91
52. Bohannon RW. Are hand-grip and knee extension strength reflective of a common construct? *Perceptual & Motor Skills.* 2012;114(2):514–8
53. Flood A, Chung A, Parker H, Kearns V, O’Sullivan TA. The use of hand grip strength as a predictor of nutrition status in hospital patients. *Clinical Nutrition.* 2014;33:106–14
54. Guerra RS, Amaral TF. Comparison of hand dynamometers in elderly people. *The Journal of Nutrition, Health & Aging.* 2009;1–6
55. Dajczman RN, Wardini R, Kasymjanova G, Prefontaine D. Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation. *Can Respir J* 2015;22(4):225–229.
56. Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. *Eur Respir J.* 2005;26(4):703–19.

57. Hasselgren P, Alamdari N, Aversa Z, Gonnella P, J Smith I. Corticosteroid and muscle wasting role of transcription factors, nuclear cofactors, and hyperacetylation. *Curr Opin Clin Nutr Metab Care*. 2010 Jul;13(4):423–8.
58. Claus F Vogelmeier. Systemic steroids in COPD. *Respiratory Research*. 2014;**15**–38.
59. Hu Z, Wang H, Lee H, Jie Du, and Mitch W. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. *J Clin Invest*. 2009 Oct 1; 119(10): 3059–3069.
60. Gea J, Pascual S, Casadevall C, Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. *J Thorac Dis* 2015;7(10):E418–E438.
61. Nele C, Karen M, and Ghislaine G. Musculoskeletal disorders in chronic obstructive pulmonary disease. *BioMed Research International*. 2014.
62. Meyer A, Zoll J, Charles A. “Skeletal muscle mitochondrial dysfunction during chronic obstructive pulmonary disease: central actor and therapeutic target,” *Experimental Physiology*.2013; 1063–1078.
63. American Thoracic Society/European Respiratory. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 159:S1–S40.
64. Maltais F, Decramer M, Casaburi R. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2014;189:15–62.
65. Coronell C, Orozco-Levi M, Méndez R. Relevance of assessing quadriceps endurance in patients with COPD. *Eur Respir J*. 2004;24: 129–36.
66. Tidball JG. Inflammatory processes in muscle injury and repair. *Am J Physiol Regul Integr Comp Physiol*. 2005;288:R345–53.
67. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argiles JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic

- system in rat soleus muscles. *Biochem Biophys Res Commun.* 2007;230:238–41.
68. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. *FASEB J.* 2008;12:871–80.
69. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin–proteasome pathway in normal and disease states. *J Nutr.* 2009;129:227S–37S.
70. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin- 1 a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc Natl Acad Sci USA.* 2010;98:14440–5.
71. Bodine SC, Latres E, Baumhueter S. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science.* 2010;294:1704–8
72. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: Health benefits throughout life. *Adv. Nutr.* 2012;3, 1–7.
73. Calder P. Marine ω -3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. *Biochim. Biophys. Acta, Mol. Cell Biol. Lipids.* 2015; 1851, 469–484
74. Calder P. Omega-3 fatty acids and inflammatory processes:from molecules to man. *Biochemical Society Transactions.* 2017;1–11
75. Vanden W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. A paradigm for gene regulation: Inflammation, NF-kappaB and PPAR. *Adv. Exp. Med. Biol.* 2003;544, 181–196.
76. Novak T, Babcock A, Jho D, Helton W, Espat N. NF- κ B inhibition by ω -3 fatty acids modulates LPS-stimulated macrophage. *Adv. Exp. Med. Biol.* 2003.
77. Lee H, Kundu J, Cha Y, Surh Y.J. Resolvin D1 stimulates efferocytosis through p50/p50-mediated suppression of tumor necrosis factor- α expression. *J Cell Sci* 2013; 126: 4037–4047
78. Tachtsis B, Camera D, Lacham O. Potential Roles of n-3 PUFAs during Skeletal Muscle Growth and Regeneration. *Nutrients.* 2018;10, 309.

79. Batlle J, Sauleda J, Balcells E, Gomeza F, Mendeza M, Rodriguez E, *et al.* Association between $\Omega 3$ and $\Omega 6$ fatty acid intakes and serum inflammatory markers in COPD. *Journal of Nutritional Biochemistry* 23. 2012;817–821.
80. Matsuyama W, Mitsuyama H, Watanabe M, Oonakahara K, Higashimoto I, Osame M *et al.* **Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD.** *CHEST* 2005; 128:3817–3827.
81. Cotogni P, Muzio G, Trombetta A, Ranieri V, Canuto R. Impact of the omega-3 to omega-6 polyunsaturated fatty acid ratio on cytokine release in human alveolar cells. *JPEN J Parenter Enteral Nutr.* 2011 Jan;35(1): 114–21.
82. Massaro M, Scoditti E, Carluccio M, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. *Prostaglandins Leukot Essent Fatty Acids.* 2008 Sep-Nov;79(3-5):109–15
83. Ramirez V, Macias M, Ortiz G, Pacheco F, Torres D, Sorto T, *et al.* Efficacy of Fish Oil on Serum of TNF α , IL-1 β , and IL-6 Oxidative Stress Markers in Multiple Sclerosis Treated with Interferon Beta-1b. *Oxidative Medicine and Cellular Longevity* Volume 2013.
84. Khosroshahi H, Houshyar J, Hesari R, Alikhah H, Vatankhah A, Safaeian A *et al.* Effect of treatment with Omega-3 fatty acids on C-reactive protein and tumor necrosis factor- α in hemodialysis patients *Saudi J Kidney Dis Transpl.* 2012;23:500–6.
85. Calder, PC. Omega-3 Fatty Acids and Inflammatory Processes. *Nutrients* 2010; 2: 355–374
86. Rees, D.; Miles, E.A.; Banerjee, T.; Wells, S.J.; Roynette, C.E.; Wahle, K.W.J.W.; Calder, P.C. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. *Am. J. Clin. Nutr.* 2006, 83, 331–342.
87. Noreen EE, Sass MJ, Crowe ML, Pabon VA, Brandauer J, Averil LK. Effects of supplemental fish oil on resting metabolic rate, body composition, and salivary cortisol in healthy adults. *J Int Soc Sports Nutr.* 2010 Oct 8;7:31

88. Smith G, Atherton P, Reeds D, Mohammed B, Rankin D, Rennie M, *et al.* Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. *Am J Clin Nutr* 2011;93:402–12
89. Krzyminska R, Czepulis N, Lewandowicz M, Zasadzka E, Suwalska A, Witowski J, *et al.* The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass. *Int. J. Environ. Res. Public Health* 2015, 12, 10558–10574
90. Kamolrat T, Gray S. The effect of eicosapentaenoic and docosahexaenoic acid on protein synthesis and breakdown in murine C2C12 myotubes. *Elsevier* 2013; 432: 593–598.
91. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM: Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. *Faseb J.* 2001, 15 (7): 1169 –1180.
92. Magee P, Pearson S, Allen J. The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation. *BioMed central Lipids in Health and Disease.*2008, 7:24
93. Smith G, Julliard S, Reeds D, Sinacore D, Klein S, Mittendorfer B. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults *Am J Clin Nutr* 2015; 102: 115–122
94. Lee S, Jo E, Khamoui A. Chronic Fish Oil Consumption with Resistance Training Improves Grip Strength, Physical Function, and Blood Pressure in Community-Dwelling Older Adults. *Sports* 2019, 7, 167.
95. Robinson SM, Jameson KA, Batelaan SF, Martin HJ, Syddall HE, Dennison EM, *et al.* Diet and its relationship with grip strength in community-dwelling older men and women: the Hertfordshire cohort study. *J Am Geriatr Soc.* 2008 Jan;56(1):84–90
96. Fulton A, Hill A, Williams M, Howe P, Frith P, Wood L, *et al.* Feasibility of omega-3 fatty acid supplementation as an adjunct therapy for people with chronic obstructive pulmonary disease. *Biomed central.* 2013;14:107

97. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. *Eur Respir J* 2008; 14: 270–274.
98. Pooja P, Vinita A. Significance of six minute walk test (6MWT) in COPD patients. *Journal of Dental and Medical Sciences (IOSR-JDMS)* e-ISSN: 2279-0853, p-ISSN: 2279-0861 Issue 7 Ver. VII. 2017; 16 :18–20
99. Bautmans I, Lambert M, Mest T. The six-minute walk test in community dwelling elderly: influence of health status. *BMC Geriatr.* 2004; 4: 6
100. Camarri B, Eastwood P, Cecins M, Thompson P, Jenkins S. Six minute walk distance in healthy subjects aged 55–75 years. *Respiratory Medicine.* 2006; 100: 658–665
101. Calder P, Laviano A, Loonqvist F, Muscaritoli M, Ohlander M, Schols A. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease : a randomized, control trial. *Journal of cachexia, sarcopenia and muscle.* 2018;9:28–40

